Instructions for Rabeprazole-SZ capsules
English product name
Rabeprazole-OBL
Release form
intestinal soluble 20 mg: 5, 7, 10, 14, 15, 20, 21, 28, 30 or 60 pcs
Description:
Intestinal-soluble capsules 1 cap.
sodium rabeprazole 20 mg
ATC codes
A02BC04 Rabeprazole
Clinical-pharmacological groups / Group affiliation
H<SUP>+</SUP>-C<SUP>+</SUP>-ATP-ase inhibitor. Antiulcer preparation
Active substance
sodium rabeprazole
Pharmacotherapy group
Proton pump inhibitor
Pharmacological effect:
The inventive antiulcer agent is used for inhibiting H+-K+-ATP-ase (proton pump). The mechanism of action is connected with oppression of the enzyme H+-K+-ATP-ase in parietal cells of the stomach, which leads to blocking the final stage of formation of hydrochloric acid. This action is dose-dependent and leads to the suppression of both basal and stimulated hydrochloric acid secretion regardless of the nature of the stimulus.
Testimony:
Stomach and duodenal ulcer disease in the exacerbation phase; stomach and duodenal ulcer disease associated with Helicobacter pylori (in combination with antibiotics); gastroesophageal reflux.
Dosage, Course and Dosage:
Inwards. The dosage regimen is set individually, depending on the indications and treatment regimen.
Use in liver disorders
Patients with liver function disorders do not need dose correction, but in patients with severe liver function disorders, rabeprazole is recommended to be used with caution.
Use in children
Use in children and adolescents under the age of 18 is contraindicated.
- Nosology (ICD codes)
- B98.0
- Helicobacter pylori as the cause of diseases classified in other categories
- K21
- Gastroesophageal reflux
- K25
- Stomach ulcer
- K26
- Duodenum ulcer
